Neurotech International Limited (NTI.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.019 (+0.00%) as of
Key statistics
- Market cap
- 30.71M
- EPS (TTM)
- -0.0100
- Dividend yield
- 0.00%
- 52-week range
- 0.0100 – 0.0210
- Beta
- 0.01
- Revenue (TTM)
- 4.73M
- Profit margin
- -138.11%
- Volume
- 1.03M
About Neurotech International Limited
Neurotech International Limited, a clinical-stage biopharmaceutical development company, focuses on development of solutions for paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy in Australia. The company develops NTI164 to treat autism spectrum disorder, paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, paediatric acute-onset neuropsychiatric syndrome, and Rett syndrome. It also engages in executing medical research projects; and developing technological devices. The company conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary cannabis strains. The company has a collaboration with The University of Sydney. Neurotech International Limited was incorporated in 2016 and is based in Melbourne, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Melbourne, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.